{"protocolSection":{"identificationModule":{"nctId":"NCT00602030","orgStudyIdInfo":{"id":"SNDX-275-0401"},"organization":{"fullName":"Syndax Pharmaceuticals","class":"INDUSTRY"},"briefTitle":"Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC","officialTitle":"A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study With a Lead in Phase of Erlotinib With or Without SNDX-275 in Patients With NSCLC After Failure In Up to Two Prior Chemotherapeutic Regimens for Advanced Disease"},"statusModule":{"statusVerifiedDate":"2022-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-01-08","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2010-02-04","type":"ACTUAL"},"completionDateStruct":{"date":"2012-02-01","type":"ACTUAL"},"studyFirstSubmitDate":"2008-01-25","studyFirstSubmitQcDate":"2008-01-25","studyFirstPostDateStruct":{"date":"2008-01-28","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-05-04","resultsFirstSubmitQcDate":"2022-06-02","resultsFirstPostDateStruct":{"date":"2022-06-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-08-18","lastUpdatePostDateStruct":{"date":"2022-08-22","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Syndax Pharmaceuticals","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the safety and efficacy of entinostat in combination with erlotinib in the treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)."},"conditionsModule":{"conditions":["Non-Small-Cell Lung Carcinoma","Carcinoma, Non-Small Cell Lung"],"keywords":["lung cancer","NSCLC","lung neoplasms","respiratory"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":141,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Lead-in Phase: Erlotinib + Entinostat 5 mg","type":"EXPERIMENTAL","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 5 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase.","interventionNames":["Drug: Entinostat","Drug: Erlotinib"]},{"label":"Lead-in Phase: Erlotinib + Entinostat 10 mg","type":"EXPERIMENTAL","description":"Erlotinib 150 mg tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase.","interventionNames":["Drug: Entinostat","Drug: Erlotinib"]},{"label":"Double-blind Phase: Erlotinib + Entinostat 10 mg","type":"EXPERIMENTAL","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Day 1 and 15 of a 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase.","interventionNames":["Drug: Entinostat","Drug: Erlotinib"]},{"label":"Double-blind Phase: Erlotinib + Placebo","type":"PLACEBO_COMPARATOR","description":"Erlotinib 150 mg, tablets, orally, daily plus placebo matching entinostat, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase.","interventionNames":["Drug: Placebo","Drug: Erlotinib"]},{"label":"Crossover Phase: Erlotinib + Entinostat 10 mg","type":"EXPERIMENTAL","description":"Participants in the Double-blind Phase Erlotinib + Placebo arm who experienced disease progression crossed over to receive open-label erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities.","interventionNames":["Drug: Entinostat","Drug: Erlotinib"]}],"interventions":[{"type":"DRUG","name":"Entinostat","description":"Entinostat tablets on Days 1 and 15 of a 28-day cycle.","armGroupLabels":["Crossover Phase: Erlotinib + Entinostat 10 mg","Double-blind Phase: Erlotinib + Entinostat 10 mg","Lead-in Phase: Erlotinib + Entinostat 10 mg","Lead-in Phase: Erlotinib + Entinostat 5 mg"],"otherNames":["SNDX-275"]},{"type":"DRUG","name":"Placebo","description":"Placebo-matching entinostat tablets on Days 1 and 15 of a 28-day cycle.","armGroupLabels":["Double-blind Phase: Erlotinib + Placebo"]},{"type":"DRUG","name":"Erlotinib","description":"Erlotinib 150 mg tablets once daily.","armGroupLabels":["Crossover Phase: Erlotinib + Entinostat 10 mg","Double-blind Phase: Erlotinib + Entinostat 10 mg","Double-blind Phase: Erlotinib + Placebo","Lead-in Phase: Erlotinib + Entinostat 10 mg","Lead-in Phase: Erlotinib + Entinostat 5 mg"],"otherNames":["Tarceva"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Identification of Safe-dose for the Phase 2 Double-blind Phase in the Lead-in Phase","description":"Safe recommended Phase 2 dose was determined based on dose-limiting toxicities (DLT) in Cycle 1. A DLT was defined as any of the following occurring in Cycle 1: Grade 3 or greater nonhematologic toxicity that was considered related to either entinostat or erlotinib or a Grade 4 hematologic toxicity lasting more than 7 days and/or resulting in a dose delay. Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 scale was used where Grade 1=mild, Grade 2=Moderate, Grade 3=Severe, medically significant, Grade 4=life-threatening and 5=death. The dose that was found to be safe is reported.","timeFrame":"Cycle 1 of Lead-in Phase"},{"measure":"4-Month Progression-free Survival (PFS) Rate in the Double-blind Phase","description":"PFS rate at 4 months was defined as the percentage of participants who are progression-free at 4 months.","timeFrame":"Month 4"}],"secondaryOutcomes":[{"measure":"Objective Response Rate (ORR) in the Double-blind Phase","description":"ORR was defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) as assessed by the investigator. CR=disappearance of all target lesions; disappearance of non-target lesions and normalization of tumor marker level. PR=At least a 30% decrease in the sum of the longest diameter of target lesions, taking at reference the baseline sum longest diameter.","timeFrame":"Month 6"},{"measure":"6-Month PFS Rate in the Double-blind Phase","description":"PFS rate at 6 months is defined as the percentage of participants who are progression-free at 6 months.","timeFrame":"Month 6"},{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) by Severity in the Double-blind Phase","description":"An AE is defined as any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. Worsening of a pre-existing medical condition was considered an AE if there was either an increase in severity, frequency, or duration of the condition or an association with significantly worse outcomes. A TEAE is an AE that starts after the administration of study drug.\n\nA SAE is any AE that is fatal, life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth effect or other significant medical hazard.\n\nTEAE severity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 scale where Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, medically significant, Grade 4=Life-threatening and 5=Death.","timeFrame":"First dose of study drug to within 30 days past last dose (Up to 7 months)"},{"measure":"Number of Participants With Grade 3 or 4 Laboratory Variables in the Double-blind Phase","description":"Laboratory tests included tests of Hematology and Chemistry. The individual laboratory values were graded by the investigator using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 scale where Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, medically significant, Grade 4=Life-threatening and 5=Death.","timeFrame":"Day 1 and 15 of each cycle to safety follow-up 30 days past last dose (up to 7 months)"},{"measure":"Vital Sign Values: Systolic Blood Pressure in the Double-blind Phase","timeFrame":"Day 1 and 15 of each cycle to safety follow-up 30 days past last dose (up to 7 months)"},{"measure":"Vital Sign Values: Diastolic Blood Pressure in the Double-blind Phase","timeFrame":"Day 1 and 15 of each cycle to safety follow-up 30 days past last dose (up to 7 months)"},{"measure":"Vital Sign Values: Heart Rate in the Double-blind Phase","timeFrame":"Day 1 and 15 of each cycle to safety follow-up 30 days past last dose (up to 7 months)"},{"measure":"Vital Sign Values: Respiration Rate in the Double-blind Phase","timeFrame":"Day 1 and 15 of each cycle to safety follow-up 30 days past last dose (up to 7 months)"},{"measure":"Vital Sign Values: Temperature in the Double-blind Phase","timeFrame":"Day 1 and 15 of each cycle to safety follow-up 30 days past last dose (up to 7 months)"},{"measure":"Vital Sign Values: Weight in the Double-blind Phase","timeFrame":"Day 1 and 15 of each cycle to safety follow-up 30 days past last dose (up to 7 months)"},{"measure":"Cmax: Maximum Plasma Concentration of Entinostat in the Lead-in Phase","timeFrame":"Day 1 predose and 0.5, 1, 2, 4 and 6 hours after dose; Days 2 and 8 predose (entinostat alone); Day 15 predose and 0.5, 1, 2, 4, 6 and 24 hours after dose"},{"measure":"Tmax: Time to Cmax of Entinostat in the Lead-in Phase","timeFrame":"Day 1 predose and 0.5, 1, 2, 4 and 6 hours after dose; Days 2 and 8 predose (entinostat alone); Day 15 predose and 0.5, 1, 2, 4, 6 and 24 hours after dose"},{"measure":"AUC(0-24): Area Under the Concentration-time Curve From Time 0 to 24 Hours in the Lead-in Phase","timeFrame":"Day 1 predose and 0.5, 1, 2, 4 and 6 hours after dose; Days 2 and 8 predose (entinostat alone); Day 15 predose and 0.5, 1, 2, 4, 6 and 24 hours after dose"},{"measure":"AUC(0-last): Area Under the Concentration-time Curve From Time 0 to Last Quantifiable Concentration in the Lead-in Phase","timeFrame":"Day 1 predose and 0.5, 1, 2, 4 and 6 hours after dose; Days 2 and 8 predose (entinostat alone); Day 15 predose and 0.5, 1, 2, 4, 6 and 24 hours after dose"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Cytologically or histologically confirmed NSCLC of stage IIIb or IV\n* Received at least 1 but no more than 2 prior chemotherapy or chemoradiotherapy regimens for advanced NSCLC (that did not include erlotinib and valproic acid) and progressed based on radiologic evidence\n* At least 1 measurable lesion by conventional or spiral computed tomography (CT) scan\n* Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1, or 2 and life expectancy of at least 6 months\n* Paraffin-embedded tumor specimen available for correlative studies\n* Male or female over 18 years of age\n* Hemoglobin ≥ 9.0 g/dL; platelets ≥ 100 x 10\\^9/L; absolute neutrophil count (ANC) ≥ 1.5 x 10\\^9/L without the use of hematopoietic growth factors\n* Bilirubin and creatinine less than 2 times the upper limit of normal for the institution\n* Albumin ≥ 2.5 g/dL\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3 times the upper limit of normal for the institution\n* Prothrombin time less than 1.5 times the upper limit of normal for the institution\n* Potassium, magnesium and phosphorus within the normal range for the institution (supplementation is permissible)\n* Willing to use accepted and effective methods of contraception during the study (both men and women as appropriate) and for 3 months after the last dose of SNDX-275\n* Patient or legally acceptable representative has granted written informed consent before any study-specific procedure (including special screening tests) are performed\n\nExclusion Criteria\n\n* Prior stem cell transplant\n* Clinical evidence of central nervous system (CNS) involvement\n* Prior treatment with an histone deacetylase (HDAC) inhibitor or an epidermal growth factor receptor (EGFR) inhibitor\n* Currently taking known inhibitors of CYPA4, including but not limited to atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, ≥ 10 mg prednisone, and voriconazole\n* Currently taking medication(s) on the prohibited medication list\n* Prior exposure to SNDX-275\n* Systemic chemotherapy, radiotherapy, or treatment with an investigational agent without recovery to at least grade 1 or baseline before study drug administration\n* Daily treatment with ≥ 10 mg prednisone within 28 days before study drug administration\n* Local or whole brain palliative radiotherapy within 14 days before study drug administration\n* Currently active second malignancy, or any malignancy within the last 5 years other than cured basal or squamous cell skin carcinoma, cervical carcinoma in situ, carcinoma in situ of the bladder, or papillary thyroid cancer\n* Inability to swallow oral medications or a gastrointestinal malabsorption condition\n* Acute infection requiring intravenous (IV) antibiotics, antivirals, or antifungals within 14 days before study drug administration\n* Known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection\n* Another serious or uncontrolled medical condition within 90 days before study drug administration such as acute myocardial infarction, angina, ventricular arrhythmias, hypertension, diabetes mellitus, or renal or hepatic insufficiency\n* Known hypersensitivity to benzamides\n* Women who are currently pregnant or breast-feeding\n* Patient currently is enrolled in (or completed within 28 days before study drug administration) another investigational drug study\n* Patient has any kind of medical, psychiatric, or behavioral disorder that places the patient at increased risk for study participation or compromises the ability of the patient to give written informed consent and/or to comply with study procedures and requirements","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Samir Witta, MD","affiliation":"Rocky Mountain Cancer Centers","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Kartik Konduri, MD","affiliation":"Texas Oncology - Sammons Cancer Center","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Robert Raju, MD","affiliation":"Dayton Oncology","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"HOPE (Hematology Oncology Physicians & Extenders)","city":"Tucson","state":"Arizona","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"Rocky Mountain Cancer Center","city":"Denver","state":"Colorado","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"Advanced Medical Specialties","city":"Miami","state":"Florida","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Ocala Oncology Center","city":"Ocala","state":"Florida","country":"United States","geoPoint":{"lat":29.1872,"lon":-82.14009}},{"facility":"Cancer Centers of Florida","city":"Ocoee","state":"Florida","country":"United States","geoPoint":{"lat":28.56917,"lon":-81.54396}},{"facility":"Hematology Oncology Associates of Illinois","city":"Chicago","state":"Illinois","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Central Indiana Cancer Centers","city":"Indianapolis","state":"Indiana","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"Kansas City Cancer Centers","city":"Overland Park","state":"Kansas","country":"United States","geoPoint":{"lat":38.98223,"lon":-94.67079}},{"facility":"Alliance Hematology Oncology","city":"Westminster","state":"Maryland","country":"United States","geoPoint":{"lat":39.57538,"lon":-76.99581}},{"facility":"St Joseph Oncology","city":"Saint Joseph","state":"Missouri","country":"United States","geoPoint":{"lat":39.76861,"lon":-94.84663}},{"facility":"The Center for Cancer Care & Research","city":"St Louis","state":"Missouri","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Mahonig Valley Hematology Oncology Associates","city":"Boardman","state":"Ohio","country":"United States","geoPoint":{"lat":41.02423,"lon":-80.66285}},{"facility":"Dayton Oncology & Hematology","city":"Kettering","state":"Ohio","country":"United States","geoPoint":{"lat":39.6895,"lon":-84.16883}},{"facility":"Oncology Associates of Oregon","city":"Eugene","state":"Oregon","country":"United States","geoPoint":{"lat":44.05207,"lon":-123.08675}},{"facility":"Texas Oncology","city":"Amarillo","state":"Texas","country":"United States","geoPoint":{"lat":35.222,"lon":-101.8313}},{"facility":"Texas Oncology","city":"Austin","state":"Texas","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Texas Oncology","city":"Bedford","state":"Texas","country":"United States","geoPoint":{"lat":32.84402,"lon":-97.14307}},{"facility":"Texas Oncology, Sammons Cancer Center","city":"Dallas","state":"Texas","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Texas Oncology","city":"Dallas","state":"Texas","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Texas Oncology","city":"Fort Worth","state":"Texas","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"Texas Oncology","city":"Garland","state":"Texas","country":"United States","geoPoint":{"lat":32.91262,"lon":-96.63888}},{"facility":"Texas Oncology","city":"Longview","state":"Texas","country":"United States","geoPoint":{"lat":32.5007,"lon":-94.74049}},{"facility":"Texas Oncology","city":"Midland","state":"Texas","country":"United States","geoPoint":{"lat":31.99735,"lon":-102.07791}},{"facility":"Texas Oncology","city":"Odessa","state":"Texas","country":"United States","geoPoint":{"lat":31.84568,"lon":-102.36764}},{"facility":"Texas Oncology","city":"Tyler","state":"Texas","country":"United States","geoPoint":{"lat":32.35126,"lon":-95.30106}},{"facility":"Fairfax Northern Virginia Hematology-Oncology","city":"Fairfax","state":"Virginia","country":"United States","geoPoint":{"lat":38.84622,"lon":-77.30637}},{"facility":"Virginia Oncology Associates","city":"Norfolk","state":"Virginia","country":"United States","geoPoint":{"lat":36.84681,"lon":-76.28522}},{"facility":"Highline Medical Oncology","city":"Burien","state":"Washington","country":"United States","geoPoint":{"lat":47.47038,"lon":-122.34679}},{"facility":"Cancer Care Northwest","city":"Spokane","state":"Washington","country":"United States","geoPoint":{"lat":47.65966,"lon":-117.42908}},{"facility":"Yakima Valley Memorial Hospital/North Star Lodge","city":"Yakima","state":"Washington","country":"United States","geoPoint":{"lat":46.60207,"lon":-120.5059}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Participants with a diagnosis of non-small cell lung carcinoma (NSCLC) were enrolled in 5 or 10 mg entinostat plus erlotinib arms to determine the Phase 2 dose. Participants were enrolled 1:1 in treatment arms: erlotinib 150 mg + entinostat 10 mg or erlotinib 150 mg + placebo. Placebo arm could receive entinostat 10 mg in the Crossover Phase.","recruitmentDetails":"Participants took part in the study at 23 investigative sites in the United States from 8 January 2008 to 1 February 2012.","groups":[{"id":"FG000","title":"Lead-in Phase: Erlotinib + Entinostat 5 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 5 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase."},{"id":"FG001","title":"Lead-in Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase."},{"id":"FG002","title":"Double-blind Phase: Erlotinib + Placebo","description":"Erlotinib 150 mg, tablets, orally, daily plus placebo matching entinostat, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."},{"id":"FG003","title":"Double-blind Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Day 1 and 15 of a 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."},{"id":"FG004","title":"Crossover Phase: Erlotinib + Entinostat 10 mg","description":"Participants in the Double-blind Phase Erlotinib + Placebo arm who experienced disease progression crossed over to receive open-label erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities."}],"periods":[{"title":"Lead-in Phase","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Disease Progression","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]}]},{"title":"Double-blind Phase","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"65"},{"groupId":"FG003","numSubjects":"67"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Received Treatment","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"63"},{"groupId":"FG003","numSubjects":"65"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"8"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"54"},{"groupId":"FG003","numSubjects":"59"},{"groupId":"FG004","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Disease progression","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"33"},{"groupId":"FG003","numSubjects":"30"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"18"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Consent withdrawal","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Administrative decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Ineligibility","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Protocol deviation/noncompliance","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Reason not specified","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"0"}]}]},{"title":"Crossover Phase","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"16"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"16"}]}],"dropWithdraws":[{"type":"Disease Progression","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"11"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"3"}]},{"type":"Consent withdrawal","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Full Analysis Set included all randomized participants.","groups":[{"id":"BG000","title":"Lead-in Phase: Erlotinib + Entinostat 5 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 5 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase."},{"id":"BG001","title":"Lead-in Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase."},{"id":"BG002","title":"Double-blind Phase: Erlotinib + Placebo","description":"Erlotinib 150 mg, tablets, orally, daily plus placebo matching entinostat, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."},{"id":"BG003","title":"Double-blind Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Day 1 and 15 of a 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"65"},{"groupId":"BG003","value":"67"},{"groupId":"BG004","value":"141"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"72","lowerLimit":"51","upperLimit":"84"},{"groupId":"BG001","value":"63.5","lowerLimit":"46","upperLimit":"78"},{"groupId":"BG002","value":"67.0","lowerLimit":"36","upperLimit":"87"},{"groupId":"BG003","value":"66.0","lowerLimit":"32","upperLimit":"90"},{"groupId":"BG004","value":"67.1","lowerLimit":"32","upperLimit":"90"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"28"},{"groupId":"BG004","value":"53"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"43"},{"groupId":"BG003","value":"39"},{"groupId":"BG004","value":"88"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"White","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"55"},{"groupId":"BG003","value":"55"},{"groupId":"BG004","value":"119"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"11"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"3"}]},{"title":"Hispanic","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"7"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Identification of Safe-dose for the Phase 2 Double-blind Phase in the Lead-in Phase","description":"Safe recommended Phase 2 dose was determined based on dose-limiting toxicities (DLT) in Cycle 1. A DLT was defined as any of the following occurring in Cycle 1: Grade 3 or greater nonhematologic toxicity that was considered related to either entinostat or erlotinib or a Grade 4 hematologic toxicity lasting more than 7 days and/or resulting in a dose delay. Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 scale was used where Grade 1=mild, Grade 2=Moderate, Grade 3=Severe, medically significant, Grade 4=life-threatening and 5=death. The dose that was found to be safe is reported.","populationDescription":"Lead-in Safety Analysis Set included all participant who received at least one dose of study drug in the Lead-in Phase.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"milligrams (mg)","timeFrame":"Cycle 1 of Lead-in Phase","groups":[{"id":"OG000","title":"Lead-in Phase: Erlotinib + Entinostat","description":"Participants received erlotinib 150 mg, tablets, orally, daily plus entinostat 5 mg or 10 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle for up to 6 cycles in the Open-label Lead-in Phase 1 dose-finding study to identify a safe dose of entinostat in combination with erlotinib for further evaluation."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}]},{"type":"PRIMARY","title":"4-Month Progression-free Survival (PFS) Rate in the Double-blind Phase","description":"PFS rate at 4 months was defined as the percentage of participants who are progression-free at 4 months.","populationDescription":"Double-blind Per-protocol Analysis Set included all randomized participants who met key eligibility criteria, received an adequate course of treatment and who had baseline and postbaseline tumor measurements.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 4","groups":[{"id":"OG000","title":"Double-blind Phase: Erlotinib + Placebo","description":"Erlotinib 150 mg, tablets, orally, daily plus placebo matching entinostat, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."},{"id":"OG001","title":"Double-blind Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Day 1 and 15 of a 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"53"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","lowerLimit":"12.2","upperLimit":"35.8"},{"groupId":"OG001","value":"20.8","lowerLimit":"9.8","upperLimit":"31.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.505","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Adjusted Odds Ratio","paramValue":"0.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.27","ciUpperLimit":"1.89","estimateComment":"Cochran-Mantel-Haenszel estimation of odds ratio adjusted for the smoking history stratification factor, using placebo as reference group."}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) in the Double-blind Phase","description":"ORR was defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) as assessed by the investigator. CR=disappearance of all target lesions; disappearance of non-target lesions and normalization of tumor marker level. PR=At least a 30% decrease in the sum of the longest diameter of target lesions, taking at reference the baseline sum longest diameter.","populationDescription":"Double-blind Full Analysis Set included all randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 6","groups":[{"id":"OG000","title":"Double-blind Phase: Erlotinib + Placebo","description":"Erlotinib 150 mg, tablets, orally, daily plus placebo matching entinostat, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."},{"id":"OG001","title":"Double-blind Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Day 1 and 15 of a 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","lowerLimit":"2.2","upperLimit":"16.3"},{"groupId":"OG001","value":"3.0","lowerLimit":"0.0","upperLimit":"7.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.13","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Adjusted Odds Ratio","paramValue":"0.31","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.06","ciUpperLimit":"1.54","estimateComment":"Estimation of odds ratio was adjusted for the smoking history stratification factor, using placebo as reference group ."}]},{"type":"SECONDARY","title":"6-Month PFS Rate in the Double-blind Phase","description":"PFS rate at 6 months is defined as the percentage of participants who are progression-free at 6 months.","populationDescription":"Full Analysis Set included all randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Month 6","groups":[{"id":"OG000","title":"Double-blind Phase: Erlotinib + Placebo","description":"Erlotinib 150 mg, tablets, orally, daily plus placebo matching entinostat, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."},{"id":"OG001","title":"Double-blind Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Day 1 and 15 of a 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","lowerLimit":"3.2","upperLimit":"18.3"},{"groupId":"OG001","value":"11.9","lowerLimit":"4.2","upperLimit":"19.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.918","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Adjusted Odds Ratio","paramValue":"1.06","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.34","ciUpperLimit":"3.27","estimateComment":"Estimation of odds ratio was adjusted for the smoking history stratification factor, using placebo as reference group."}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) by Severity in the Double-blind Phase","description":"An AE is defined as any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. Worsening of a pre-existing medical condition was considered an AE if there was either an increase in severity, frequency, or duration of the condition or an association with significantly worse outcomes. A TEAE is an AE that starts after the administration of study drug.\n\nA SAE is any AE that is fatal, life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth effect or other significant medical hazard.\n\nTEAE severity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 scale where Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, medically significant, Grade 4=Life-threatening and 5=Death.","populationDescription":"Safety Analysis Set included all participants who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"First dose of study drug to within 30 days past last dose (Up to 7 months)","groups":[{"id":"OG000","title":"Double-blind Phase: Erlotinib + Placebo","description":"Erlotinib 150 mg, tablets, orally, daily plus placebo matching entinostat, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."},{"id":"OG001","title":"Double-blind Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Day 1 and 15 of a 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"65"}]}],"classes":[{"title":"Any SAE","categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"32"}]}]},{"title":"Any TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"65"}]}]},{"title":"Grade 1 TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"}]}]},{"title":"Grade 2 TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"12"}]}]},{"title":"Grade 3 TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"34"}]}]},{"title":"Grade 4 TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}]}]},{"title":"Grade 5 TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"12"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Grade 3 or 4 Laboratory Variables in the Double-blind Phase","description":"Laboratory tests included tests of Hematology and Chemistry. The individual laboratory values were graded by the investigator using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 scale where Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, medically significant, Grade 4=Life-threatening and 5=Death.","populationDescription":"Safety Population included all participants who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 and 15 of each cycle to safety follow-up 30 days past last dose (up to 7 months)","groups":[{"id":"OG000","title":"Double-blind Phase: Erlotinib + Placebo","description":"Erlotinib 150 mg, tablets, orally, daily plus placebo matching entinostat, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."},{"id":"OG001","title":"Double-blind Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Day 1 and 15 of a 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"65"}]}],"classes":[{"title":"White Blood Count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Absolute Neutrophil Count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"Lymphocytes decreased","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"18"}]}]},{"title":"Platelets decreased","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"Phosphorus decreased","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"}]}]},{"title":"Alanine aminotransferase increased","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}]},{"title":"Sodium decreased","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}]}]},{"title":"Glucose increased","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}]},{"title":"Albumin decreased","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]},{"title":"Potassium decreased","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Aspartate aminotransferase increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Bilirubin increased","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"Creatinine abnormal","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Magnesium decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Potassium increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Calcium increased","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Calcium decreased","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Vital Sign Values: Systolic Blood Pressure in the Double-blind Phase","populationDescription":"Safety Population included all participants who received at least one dose of study drug. Number analyzed is the number of participants with data available.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mm Hg","timeFrame":"Day 1 and 15 of each cycle to safety follow-up 30 days past last dose (up to 7 months)","groups":[{"id":"OG000","title":"Double-blind Phase: Erlotinib + Placebo","description":"Erlotinib 150 mg, tablets, orally, daily plus placebo matching entinostat, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."},{"id":"OG001","title":"Double-blind Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Day 1 and 15 of a 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"65"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"65"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"125.3","spread":"17.41"},{"groupId":"OG001","value":"126.0","spread":"18.93"}]}]},{"title":"Minimum Post-Baseline Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"112.4","spread":"13.95"},{"groupId":"OG001","value":"105.0","spread":"15.14"}]}]},{"title":"Maximum Post-Baseline Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"135.5","spread":"15.74"},{"groupId":"OG001","value":"132.5","spread":"20.64"}]}]}]},{"type":"SECONDARY","title":"Vital Sign Values: Diastolic Blood Pressure in the Double-blind Phase","populationDescription":"Safety Population included all participants who received at least one dose of study drug. Number analyzed is the number of participants with data available.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mm Hg","timeFrame":"Day 1 and 15 of each cycle to safety follow-up 30 days past last dose (up to 7 months)","groups":[{"id":"OG000","title":"Double-blind Phase: Erlotinib + Placebo","description":"Erlotinib 150 mg, tablets, orally, daily plus placebo matching entinostat, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."},{"id":"OG001","title":"Double-blind Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Day 1 and 15 of a 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"65"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"65"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.5","spread":"10.06"},{"groupId":"OG001","value":"72.1","spread":"10.38"}]}]},{"title":"Minimum Post-Baseline Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.7","spread":"9.31"},{"groupId":"OG001","value":"61.3","spread":"9.70"}]}]},{"title":"Maximum Post-Baseline Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78.8","spread":"9.92"},{"groupId":"OG001","value":"78.5","spread":"10.09"}]}]}]},{"type":"SECONDARY","title":"Vital Sign Values: Heart Rate in the Double-blind Phase","populationDescription":"Safety Population included all participants who received at least one dose of study drug. Number analyzed is the number of participants with data available.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"beats per minute (bpm)","timeFrame":"Day 1 and 15 of each cycle to safety follow-up 30 days past last dose (up to 7 months)","groups":[{"id":"OG000","title":"Double-blind Phase: Erlotinib + Placebo","description":"Erlotinib 150 mg, tablets, orally, daily plus placebo matching entinostat, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."},{"id":"OG001","title":"Double-blind Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Day 1 and 15 of a 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"65"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"65"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":"15.96"},{"groupId":"OG001","value":"85.6","spread":"17.41"}]}]},{"title":"Minimum Post-Baseline Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"78.5","spread":"16.75"},{"groupId":"OG001","value":"79.7","spread":"15.19"}]}]},{"title":"Maximum Post-Baseline Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":"15.24"},{"groupId":"OG001","value":"102.1","spread":"17.12"}]}]}]},{"type":"SECONDARY","title":"Vital Sign Values: Respiration Rate in the Double-blind Phase","populationDescription":"Safety Population included all participants who received at least one dose of study drug. Number analyzed is the number of participants with data available.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"breaths per minute","timeFrame":"Day 1 and 15 of each cycle to safety follow-up 30 days past last dose (up to 7 months)","groups":[{"id":"OG000","title":"Double-blind Phase: Erlotinib + Placebo","description":"Erlotinib 150 mg, tablets, orally, daily plus placebo matching entinostat, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."},{"id":"OG001","title":"Double-blind Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Day 1 and 15 of a 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"65"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"65"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":"2.56"},{"groupId":"OG001","value":"17.9","spread":"2.46"}]}]},{"title":"Minimum Post-Baseline Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.2","spread":"2.62"},{"groupId":"OG001","value":"16.6","spread":"2.34"}]}]},{"title":"Maximum Post-Baseline Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.2","spread":"3.14"},{"groupId":"OG001","value":"20.1","spread":"2.66"}]}]}]},{"type":"SECONDARY","title":"Vital Sign Values: Temperature in the Double-blind Phase","populationDescription":"Safety Population included all participants who received at least one dose of study drug. Number analyzed is the number of participants with data available.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"degrees Celsius (C)","timeFrame":"Day 1 and 15 of each cycle to safety follow-up 30 days past last dose (up to 7 months)","groups":[{"id":"OG000","title":"Double-blind Phase: Erlotinib + Placebo","description":"Erlotinib 150 mg, tablets, orally, daily plus placebo matching entinostat, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."},{"id":"OG001","title":"Double-blind Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Day 1 and 15 of a 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"65"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"65"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.5","spread":"0.84"},{"groupId":"OG001","value":"97.6","spread":"0.90"}]}]},{"title":"Minimum Post-Baseline Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.9","spread":"1.15"},{"groupId":"OG001","value":"97.0","spread":"0.91"}]}]},{"title":"Maximum Post-Baseline Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":"0.90"},{"groupId":"OG001","value":"98.5","spread":"1.12"}]}]}]},{"type":"SECONDARY","title":"Vital Sign Values: Weight in the Double-blind Phase","populationDescription":"Safety Population included all participants who received at least one dose of study drug. Number analyzed is the number of participants with data available.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"kilograms (kg)","timeFrame":"Day 1 and 15 of each cycle to safety follow-up 30 days past last dose (up to 7 months)","groups":[{"id":"OG000","title":"Double-blind Phase: Erlotinib + Placebo","description":"Erlotinib 150 mg, tablets, orally, daily plus placebo matching entinostat, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."},{"id":"OG001","title":"Double-blind Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Day 1 and 15 of a 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"65"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"65"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.9","spread":"16.83"},{"groupId":"OG001","value":"74.3","spread":"17.48"}]}]},{"title":"Minimum Post-Baseline Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.5","spread":"16.98"},{"groupId":"OG001","value":"70.0","spread":"15.71"}]}]},{"title":"Maximum Post-Baseline Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.6","spread":"16.97"},{"groupId":"OG001","value":"74.3","spread":"16.93"}]}]}]},{"type":"SECONDARY","title":"Cmax: Maximum Plasma Concentration of Entinostat in the Lead-in Phase","populationDescription":"Pharmacokinetic (PK) Population included all participants who had blood collected for PK parameters in the Lead-in Phase. Number analyzed is the number of participants with data available at the give timepoint.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Day 1 predose and 0.5, 1, 2, 4 and 6 hours after dose; Days 2 and 8 predose (entinostat alone); Day 15 predose and 0.5, 1, 2, 4, 6 and 24 hours after dose","groups":[{"id":"OG000","title":"Lead-in Phase: Erlotinib + Entinostat 5 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 5 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase."},{"id":"OG001","title":"Lead-in Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Day 1 (entinostat alone)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":"20.6"},{"groupId":"OG001","value":"123.1","spread":"136.4"}]}]},{"title":"Day 15 (entinostat + erlotinib)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.2","spread":"41.0"},{"groupId":"OG001","value":"99.4","spread":"132.5"}]}]}]},{"type":"SECONDARY","title":"Tmax: Time to Cmax of Entinostat in the Lead-in Phase","populationDescription":"PK Population included all participants who had PK samples collected in the Lead-in Phase. Number analyzed is the number of participants with data available at the give time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"hour","timeFrame":"Day 1 predose and 0.5, 1, 2, 4 and 6 hours after dose; Days 2 and 8 predose (entinostat alone); Day 15 predose and 0.5, 1, 2, 4, 6 and 24 hours after dose","groups":[{"id":"OG000","title":"Lead-in Phase: Erlotinib + Entinostat 5 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 5 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase."},{"id":"OG001","title":"Lead-in Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Day 1 (entinostat alone)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"0.29"},{"groupId":"OG001","value":"0.50","spread":"0.00"}]}]},{"title":"Day 15 (entinostat + erlotinib)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"0.9"},{"groupId":"OG001","value":"1.3","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"AUC(0-24): Area Under the Concentration-time Curve From Time 0 to 24 Hours in the Lead-in Phase","populationDescription":"PK Population included all participants who had PK samples collected in the Lead-in Phase. Number analyzed is the number of participants with data available at the given timepoint","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng*hr/mL","timeFrame":"Day 1 predose and 0.5, 1, 2, 4 and 6 hours after dose; Days 2 and 8 predose (entinostat alone); Day 15 predose and 0.5, 1, 2, 4, 6 and 24 hours after dose","groups":[{"id":"OG000","title":"Lead-in Phase: Erlotinib + Entinostat 5 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 5 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase."},{"id":"OG001","title":"Lead-in Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Day 1 (entinostat alone)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.5","spread":"12.2"},{"groupId":"OG001","value":"133.3","spread":"84.8"}]}]},{"title":"Day 15 (entinostat + erlotinib)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"51.7","spread":"24.6"},{"groupId":"OG001","value":"110.2","spread":"92.3"}]}]}]},{"type":"SECONDARY","title":"AUC(0-last): Area Under the Concentration-time Curve From Time 0 to Last Quantifiable Concentration in the Lead-in Phase","populationDescription":"PK Population included all participants who had PK samples collected during the Lead-in Phase. Number analyzed is the number of participants with data available at the given timepoint.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng*hr/mL","timeFrame":"Day 1 predose and 0.5, 1, 2, 4 and 6 hours after dose; Days 2 and 8 predose (entinostat alone); Day 15 predose and 0.5, 1, 2, 4, 6 and 24 hours after dose","groups":[{"id":"OG000","title":"Lead-in Phase: Erlotinib + Entinostat 5 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 5 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase."},{"id":"OG001","title":"Lead-in Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}]}],"classes":[{"title":"Day 1 (entinostat alone)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"152.1","spread":"26.3"},{"groupId":"OG001","value":"325.8","spread":"193.1"}]}]},{"title":"Day 15 (entinostat + erlotinib)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"51.7","spread":"24.6"},{"groupId":"OG001","value":"106.4","spread":"96.8"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"First dose of study drug to 30 days past last dose (up to 7 months)","description":"Number of participants at risk for Serious and Other Adverse events was based on the Safety Population that included all participants who received at least one dose of study drug.","eventGroups":[{"id":"EG000","title":"Lead-in Phase: Erlotinib + Entinostat 5 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 5 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase.","seriousNumAffected":2,"seriousNumAtRisk":3,"otherNumAffected":3,"otherNumAtRisk":3},{"id":"EG001","title":"Lead-in Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Lead-in Phase.","seriousNumAffected":3,"seriousNumAtRisk":6,"otherNumAffected":6,"otherNumAtRisk":6},{"id":"EG002","title":"Double-blind Phase: Erlotinib + Placebo","description":"Erlotinib 150 mg, tablets, orally, daily plus placebo matching entinostat, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase.","seriousNumAffected":29,"seriousNumAtRisk":63,"otherNumAffected":63,"otherNumAtRisk":63},{"id":"EG003","title":"Double-blind Phase: Erlotinib + Entinostat 10 mg","description":"Erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Day 1 and 15 of a 28-day cycle until disease progression or intolerable toxicities for up to 6 cycles in the Double-blind Phase.","seriousNumAffected":32,"seriousNumAtRisk":65,"otherNumAffected":64,"otherNumAtRisk":65},{"id":"EG004","title":"Crossover Phase: Erlotinib + Entinostat 10 mg","description":"Participants in the Double-blind Phase Erlotinib + Placebo arm who experienced disease progression crossed over to receive open-label erlotinib 150 mg, tablets, orally, daily plus entinostat 10 mg, tablets, orally, on Days 1 and 15 of each 28-day cycle until disease progression or intolerable toxicities.","seriousNumAffected":5,"seriousNumAtRisk":16,"otherNumAffected":14,"otherNumAtRisk":16}],"seriousEvents":[{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3},{"groupId":"EG001","numAffected":2,"numAtRisk":6},{"groupId":"EG002","numAffected":16,"numAtRisk":63},{"groupId":"EG003","numAffected":7,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Monoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Pain in extremity","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":2,"numAtRisk":63},{"groupId":"EG003","numAffected":3,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":2,"numAtRisk":63},{"groupId":"EG003","numAffected":3,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Anemia Group","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":2,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":2,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":2,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":2,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":2,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Accidental overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Cardia disorder","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Dehydration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Diaphragmatic paralysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Hepatotoxicity","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Hernia obstructive","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Hypotension","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Hypovolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Lung infiltration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Pelvic fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Peripheral artery aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Respiratory disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Thrombocytopenia Group","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Vena cava thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Duodenal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Duodenal ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Genital rash","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":2,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Malignant pleural effusion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Metastases to spine","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Non-small cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Superior vena caval occlusion","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Congestive cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Gastroenteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Hemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]}],"otherEvents":[{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":6,"numAtRisk":6},{"groupId":"EG002","numAffected":30,"numAtRisk":63},{"groupId":"EG003","numAffected":37,"numAtRisk":65},{"groupId":"EG004","numAffected":3,"numAtRisk":16}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":3},{"groupId":"EG001","numAffected":5,"numAtRisk":6},{"groupId":"EG002","numAffected":32,"numAtRisk":63},{"groupId":"EG003","numAffected":38,"numAtRisk":65},{"groupId":"EG004","numAffected":5,"numAtRisk":16}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":3,"numAtRisk":6},{"groupId":"EG002","numAffected":16,"numAtRisk":63},{"groupId":"EG003","numAffected":32,"numAtRisk":65},{"groupId":"EG004","numAffected":4,"numAtRisk":16}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3},{"groupId":"EG001","numAffected":3,"numAtRisk":6},{"groupId":"EG002","numAffected":35,"numAtRisk":63},{"groupId":"EG003","numAffected":33,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":2,"numAtRisk":6},{"groupId":"EG002","numAffected":7,"numAtRisk":63},{"groupId":"EG003","numAffected":11,"numAtRisk":65},{"groupId":"EG004","numAffected":2,"numAtRisk":16}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":2,"numAtRisk":6},{"groupId":"EG002","numAffected":9,"numAtRisk":63},{"groupId":"EG003","numAffected":8,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":2,"numAtRisk":6},{"groupId":"EG002","numAffected":7,"numAtRisk":63},{"groupId":"EG003","numAffected":4,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":2,"numAtRisk":6},{"groupId":"EG002","numAffected":11,"numAtRisk":63},{"groupId":"EG003","numAffected":20,"numAtRisk":65},{"groupId":"EG004","numAffected":4,"numAtRisk":16}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":2,"numAtRisk":6},{"groupId":"EG002","numAffected":8,"numAtRisk":63},{"groupId":"EG003","numAffected":18,"numAtRisk":65},{"groupId":"EG004","numAffected":5,"numAtRisk":16}]},{"term":"Thrombocytopenia group","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":2,"numAtRisk":6},{"groupId":"EG002","numAffected":2,"numAtRisk":63},{"groupId":"EG003","numAffected":10,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":2,"numAtRisk":6},{"groupId":"EG002","numAffected":7,"numAtRisk":63},{"groupId":"EG003","numAffected":11,"numAtRisk":65},{"groupId":"EG004","numAffected":2,"numAtRisk":16}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":2,"numAtRisk":6},{"groupId":"EG002","numAffected":8,"numAtRisk":63},{"groupId":"EG003","numAffected":20,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":6,"numAtRisk":63},{"groupId":"EG003","numAffected":2,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Anemia group","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":7,"numAtRisk":63},{"groupId":"EG003","numAffected":15,"numAtRisk":65},{"groupId":"EG004","numAffected":3,"numAtRisk":16}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":10,"numAtRisk":63},{"groupId":"EG003","numAffected":26,"numAtRisk":65},{"groupId":"EG004","numAffected":2,"numAtRisk":16}]},{"term":"Balance disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":6,"numAtRisk":63},{"groupId":"EG003","numAffected":9,"numAtRisk":65},{"groupId":"EG004","numAffected":3,"numAtRisk":16}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Dry throat","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":4,"numAtRisk":63},{"groupId":"EG003","numAffected":5,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":4,"numAtRisk":63},{"groupId":"EG003","numAffected":3,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Gingival bleeding","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":7,"numAtRisk":63},{"groupId":"EG003","numAffected":6,"numAtRisk":65},{"groupId":"EG004","numAffected":3,"numAtRisk":16}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Monarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Neutropenia group","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Pharyngolaryngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":2,"numAtRisk":63},{"groupId":"EG003","numAffected":4,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":5,"numAtRisk":63},{"groupId":"EG003","numAffected":4,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":6,"numAtRisk":63},{"groupId":"EG003","numAffected":9,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Flushing","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Hair growth abnormal","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":6,"numAtRisk":63},{"groupId":"EG003","numAffected":3,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Nail disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Photophobia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":2,"numAtRisk":63},{"groupId":"EG003","numAffected":8,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Xerosis","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":11,"numAtRisk":63},{"groupId":"EG003","numAffected":21,"numAtRisk":65},{"groupId":"EG004","numAffected":3,"numAtRisk":16}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":5,"numAtRisk":63},{"groupId":"EG003","numAffected":10,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":12,"numAtRisk":63},{"groupId":"EG003","numAffected":10,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":3,"numAtRisk":63},{"groupId":"EG003","numAffected":9,"numAtRisk":65},{"groupId":"EG004","numAffected":4,"numAtRisk":16}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":4,"numAtRisk":63},{"groupId":"EG003","numAffected":8,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":8,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":8,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":6,"numAtRisk":63},{"groupId":"EG003","numAffected":7,"numAtRisk":65},{"groupId":"EG004","numAffected":2,"numAtRisk":16}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":2,"numAtRisk":63},{"groupId":"EG003","numAffected":5,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":3,"numAtRisk":63},{"groupId":"EG003","numAffected":5,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":63},{"groupId":"EG003","numAffected":5,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":3,"numAtRisk":63},{"groupId":"EG003","numAffected":4,"numAtRisk":65},{"groupId":"EG004","numAffected":2,"numAtRisk":16}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":4,"numAtRisk":63},{"groupId":"EG003","numAffected":4,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":4,"numAtRisk":63},{"groupId":"EG003","numAffected":3,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":5,"numAtRisk":63},{"groupId":"EG003","numAffected":3,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":5,"numAtRisk":63},{"groupId":"EG003","numAffected":2,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":5,"numAtRisk":63},{"groupId":"EG003","numAffected":2,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":6,"numAtRisk":63},{"groupId":"EG003","numAffected":1,"numAtRisk":65},{"groupId":"EG004","numAffected":0,"numAtRisk":16}]},{"term":"Cellulitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":3,"numAtRisk":16}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":2,"numAtRisk":16}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":2,"numAtRisk":16}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":2,"numAtRisk":16}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":2,"numAtRisk":16}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":2,"numAtRisk":16}]},{"term":"Blood albumin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Decubitus ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":3,"numAtRisk":63},{"groupId":"EG003","numAffected":4,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Eye discharge","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Eye infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Fungal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":2,"numAtRisk":63},{"groupId":"EG003","numAffected":4,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Hypersomnia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Hypovolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Limb discomfort","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Localised infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Lung disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Nasal dryness","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Peroneal nerve palsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Protein total decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Sensation of heaviness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Skin lesion","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Vaginal haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Vulvovaginal dryness","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":3,"numAtRisk":63},{"groupId":"EG003","numAffected":4,"numAtRisk":65},{"groupId":"EG004","numAffected":1,"numAtRisk":16}]},{"term":"Appetite disorder","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":4,"numAtRisk":63},{"groupId":"EG003","numAffected":0,"numAtRisk":65},{"groupId":"EG004","numAffected":3,"numAtRisk":16}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Publication of the results of the multi-center Study shall not be made before the first multi-site publication by Sponsor or Publications Committee. No Public Presentation by Institution or Investigator will be made until Study Documentation/Results from all sites are received and analyzed by Sponsor. Separate publication by Investigator will be delayed for a period of 18 months until the initial publication by Committee or Sponsor, or a determination is made not to make such publication."},"pointOfContact":{"title":"Michael Meyers, MD, PhD, Chief Medical Officer","organization":"Syndax Pharmaceuticals, Inc.","email":"mmeyers@syndax.com","phone":"+1-646-690-7620"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D008175","term":"Lung Neoplasms"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C118739","term":"entinostat"},{"id":"D000069347","term":"Erlotinib Hydrochloride"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}